MedTrace Logo

Sevoflurane in COVID-19 ARDS (SevCov)

NCT04355962 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2021-07-19

No results posted yet for this study

Summary

The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.

Conditions

  • ARDS, Human
  • Coronavirus

Interventions

DRUG

Sevoflurane

Sedation with sevoflurane (etSevo 0.5-1.5 Vol %) for 48 hours in patients with COVID-19 ARDS

DRUG

Intravenous drug

Intravenous sedation in control group will be continued as initiated at the ICU e.g. propofol, fentanyl, midazolam, dexmedetomidine

Sponsors & Collaborators

  • Kantonsspital Münsterlingen

    collaborator OTHER

  • Triemli Hospital

    collaborator OTHER

  • Cantonal Hospital of St. Gallen

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Beatrice Beck Schimmer, Prof · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-23
Primary Completion
2021-06-25
Completion
2021-07-16

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04355962 on ClinicalTrials.gov